CardioSenseSystem Compared Study Regarding Efficacy and Safety in the Monitoring of ECG

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-30

Study Completion Date

2020-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, controlled, comparative clinical trial of a new ECG monitoring system CardioSenseSystem prior CE marking. The aim of the study is to demonstrate that the CardioSenseSystem's cable-free ECG monitoring system (investigational device) is equivalent or better than traditional and accepted industry standard for cable-based ECG monitoring system (control device). In this study accepted industry standard is Philips Intellivue. In order to investigate this, the study will measure ECG monitoring interruptions, management time and alarm performance. The study population will consist of sixty (60) adult subjects requiring ECG and that are fulfilling the eligibility criteria for study participation. The subjects will be using both the investigational device and the control device simultaneous for measuring data loss, management time and alarm function up to 24 hours.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combining Accelerometer, Gyroscope, Sound, Electrocardiography and Photoplethysmography Data in Cardiac Monitoring

NCT06422468

Atrial Fibrillation

RECRUITING NA

EVAluation of the Non Inferiority of Interpretability of Cardiokin Compared to Holter

NCT03932227

Healthy Volunteers

COMPLETED NA

Cardiac Monitor Employee Study

NCT03826225

Arrhythmias, Cardiac

COMPLETED

Wireless ECG Body Sensor During Field Testing

NCT04786509

ECG Electrode Site Reaction

COMPLETED

Heartbeat Sensitivity Calibration Using the ECG Accessory

NCT01268007

ECG Comparisons in Normal Healthy Subject

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A prospective, controlled and comparative clinical trial before CE marking of a new ECG monitoring system CardioSenseSystem. The study population will consist of sixty (60) adult subjects requiring ECG and that are fulfilling the eligibility criteria for study participation. The subjects will be monitored by both the investigational device and the control device for measuring data loss, management time and alarm function up to 24 hours. The duration of the study is estimated to 4 months.

CardioSenseSystem is designed to provide wireless high-quality ECG monitoring. The system developed by Novosense AB consists of three components: the CardioPatch, the Novosense Base Station and the Back-End System. The CardioPatch is a wireless sensor capable to record and transmit ECG data. The CardioPatch send ECG data to the Novosense Base Station, which is the receiving unit. The Back-End System is used for presentation, storage and processing of ECG information. The CardioPatch sensor is applied to the body with an adhesive in the same way as a traditional ECG electrode. In contrast, the CardioPatch is a fully integrated unit containing electrodes, ECG amplifier and a radio transmitter. Novosense's wireless ECG sensors, CardioPatch, transmits the ECG signal 24 hours to the Novosense Base Station receiver.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Arrythmias Unstable Angina Heart Valve Disorders Disorder of Aorta

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

The study participants will be using both the experimental device and the control device simultaneously throughout the study participation. The participant will thereby act as its own control.

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ECG monitoring system CardioSenseSystem group

Group Type EXPERIMENTAL

CardioSenseSystem

Intervention Type DEVICE

CardioSensySystem is a novel wireless ECG monitoring system developed by Novosense AB for monitoring of ECG in health care departments.

ECG monitoring system Philips Intellivue

Group Type ACTIVE_COMPARATOR

Philips Intellivue

Intervention Type DEVICE

Philips Intellivue in an established ECG monitoring system used at the clinical investigational device.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CardioSenseSystem

CardioSensySystem is a novel wireless ECG monitoring system developed by Novosense AB for monitoring of ECG in health care departments.

Intervention Type DEVICE

Philips Intellivue

Philips Intellivue in an established ECG monitoring system used at the clinical investigational device.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female at least 18 years old.
2. Patient hospitalized at the investigational site and in need of ECG monitoring.
3. Patient with expected alarms during the 24 hours ECG monitoring.
4. Patient who has been informed of the clinical trials purpose, limitations and relevance, and who has voluntarily agreed to participation in the clinical trial by signing the informed consent form.

Exclusion Criteria

1. Patient with burns.
2. Patient with known allergy or sensitivity to any of the compositions in CardioPatch.
3. Patient with infection in the area where the electrodes are to be placed.
4. Patient with fragile skin (eg after prolonged cortisone treatment).
5. Patient with open sternum / sternum (eg severe heart failure postoperatively) or treatment for infection of the sternum.
6. Patient with mechanical auxiliary heart or ECMO.
7. Patient with implantable defibrillator.
8. Severely ill patient during end of life.
9. Patient participating in any other clinical trial.
10. Patient where the investigator judge that participation may be risky for the patient or obstruct or interfere the implementation of the trial as approved.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No